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A b s t r a c t
Introduction: There are limited data describing bioresorbable vascular scaffold (BVS) implantation in complex lesions. Only 
short-term clinical outcomes are available for patients with acute coronary syndrome (ACS).
Aim: To evaluate 12-month clinical outcome, safety and effectiveness of BVS implantation in complex lesions and in stable 
angina (SA) or ACS.
Material and methods: Five hundred ninety-one patients with SA/ACS were enrolled between October 2012 and November 
2013 in 30 invasive cardiology centres in Poland. At least one BVS implantation during percutaneous coronary intervention (PCI) was 
the only inclusion criteria. The clinical endpoint was the occurrence of a major adverse cardiovascular event (MACE) (all-cause death, 
myocardial infarction (MI), clinically driven target lesion revascularisation (TLR) with urgent PCI or target vessel revascularisation 
(TVR) with urgent coronary artery bypass grafting (CABG)) and device-oriented composite endpoint (DOCE) (cardiac death, urgent 
target vessel revascularisation with PCI/CABG, target vessel MI) during 12-month follow-up.
Results: After 12 months TLR with urgent PCI was significantly more often reported in patients with diagnosed UA (4.59%; 
p < 0.02) in comparison with other PCI indications. No significant differences were found in terms of composite MACE endpoint, 
cumulative MACE (p = 0.09), stent thrombosis (p = 0.2) or restenosis (p = 0.2). There were no significant differences in cumula-
tive MACE and composite MACE endpoint between patients with no/mild versus moderate/severe tortuosity and no/mild versus 
moderate/severe calcification of the target vessel. No significant difference was found between groups of patients with or without 
bifurcation of the target vessel. Device-oriented composite endpoint was significantly more often reported in the ACS group (3.2% 
vs. 0.47%; p < 0.03), most frequently in patients with diagnosed UA (5.5%).
Conclusions: Bioresorbable vascular scaffold can be successfully and safely used for ACS treatment and in lesions of higher 
complexity.
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Introduction
The introduction of the bioresorbable vascular scaf-
fold (BVS) is a new approach in interventional cardiology 
[1]. It provides transient vessel support and drug delivery 
without the potential long-term limitations of metallic 
implants [2]. Prolonged contact with a  foreign material 
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can lead to limited vasomotion, chronic inflammation, late 
expansive remodelling and late thrombosis, and may pre-
clude surgical revascularisation. After complete bioresorp-
tion in 2–3 years [3, 4], the BVS leaves the vessel covered 
with a healthy endothelium and restored vasomotion [5]. 
Data presented in the ABSORB trials showed the efficacy 
and safety of BVS [6] and their unique advantage in the 
restoration of vasomotion [7]. Long-term results are still 
limited to a small number of patients [7]. There are lim-
ited data describing BVS implantation in complex lesions 
such as bifurcations, calcified lesions or severely tortuous 
vessels. Only short-term clinical outcomes are available for 
patients with acute coronary syndrome (ACS) [8].
Aim
We sought to evaluate 12-month clinical outcome, 
safety and effectiveness of BVS implantation in lesions of 
higher complexity and in the setting of both stable angi-
na (SA) and ACS in a Polish contemporary registry study. 
Material and methods
This report represents a  one-arm retrospective ob-
servational registry study, which enrolled patients in 
30 invasive cardiology centres in Poland. Data describ-
ing baseline clinical and demographic characteristics of 
the patients, past medical history, angiography and per-
cutaneous coronary intervention (PCI) details as well as 
periprocedural and in-hospital outcomes have been re-
ported in the previous paper [9]. Patients with at least 
one BVS implantation during the index PCI were included 
in the registry. There were no additional inclusion or ex-
clusion criteria. The study group consisted of 591 consec-
utive patients who underwent PCI between October 2012 
and November 2013. The 12-month follow-up was com-
pleted in 79% (468 patients). The bioethics committee of 
the Jagiellonian University in Krakow approved the proto-
col of the registry. The clinical endpoint for the study was 
the occurrence of a major adverse cardiovascular event 
(MACE) and device-oriented composite endpoint (DOCE) 
during 12-month follow-up. The MACE was defined as 
all-cause death, myocardial infarction (MI), clinically 
driven target lesion revascularisation (TLR) with urgent 
PCI or target vessel revascularisation (TVR) with urgent 
coronary artery bypass grafting (CABG). Device-oriented 
composite endpoint included cardiac death, TVR with 
urgent PCI or CABG and target vessel MI. All individual 
components of events and device thrombosis were de-
fined by the Academic Research Consortium (ARC) crite-
ria [10]. Occurrences of adverse events were assessed at 
regular clinical follow-up in hospital or by standardised 
telephone interview. 
Statistical analysis
Standard descriptive statistics were used in the anal-
ysis. Quantitative variables were described using means 
and standard deviation. Categorical variables were pre-
sented with counts and as percentages. The level of sta-
tistical significance was set at p ≤ 0.05. All calculations 
were done with JMP 9.0.0 software (SAS Institute Inc., 
Cary, NC). This study was executed in cooperation with 
an independent contract research organisation – Krakow 
Cardiovascular Research Institute (KCRI, Poland).
Results
Complete baseline clinical and demographic char-
acteristics of the included 591 patients were reported 
previously [9]. Technical delivery success was achieved 
in 100% of cases. One-year clinical outcomes of included 
patients are summarised in Table I. After 12 months there 
were no significant differences in rates of stent thrombo-
sis (ST) (p = 0.2), stent restenosis (SR) (p = 0.2), all-cause 
death (p = 0.2), occurrence of MI (p = 0.9), TVR with ur-
gent CABG or cumulative MACE (p = 0.09) in comparison 
between patients with SA, unstable angina (UA), non-ST 
elevation myocardial infarction (NSTEMI) and ST eleva-
tion myocardial infarction (STEMI). Target lesion revas-
cularisation with urgent PCI was significantly more often 
performed in patients with diagnosed UA in comparison 
with SA, STEMI and NSTEMI groups (respectively: 4.59% 
vs. 0.47% vs. 1.82% vs. 0.0%; p < 0.02). There were no 
significant differences in cumulative MACE and compos-
ite MACE endpoint between patients with diagnosed ACS 
and SA (Table I). Kaplan-Meier curves for MACE incidence 
are presented in Figure 1. Device-oriented composite 
endpoint was significantly more often reported in the 
ACS group (Table I), the most often in patients with UA 
in comparison with other PCI indications (respectively: 
5.5% vs. 0.47% vs. 0.0% vs. 3.7%; p < 0.006). Kaplan-Mei-
er curves for DOCE incidence are presented in Figure 2. 
No significant differences were observed in clinical out-
come in comparison between patients with simple (ACC/
AHA type A or B1) and complex lesions (ACC/AHA type B2 
or C). There were no significant differences in cumulative 
DOCE, cumulative MACE and composite MACE endpoint 
between patients with no or mild vs. moderate or severe 
tortuosity of the target vessel (Table II). Furthermore, no 
significant differences in 12 months clinical outcome 
were observed in comparison of patients with no or mild 
vs. moderate or severe calcification in the target vessel 
(Table III). Likewise, data were obtained between groups 
of patients with or without bifurcation of the target ves-
sel (Table IV). The first case of ST occurred within 30 days 
after the procedure (STEMI group), the second at 90 days 
after BVS implantation (UA group). The majority of events 
occurred within six months after BVS implantation. 
Discussion
According to the present data, DOCE was significantly 
more frequent in the ACS group, with the highest inci-
dence in patients with diagnosed UA. Furthermore, TLR 
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Table I. Clinical outcome, device oriented composite endpoint and major adverse cardiovascular events after 
12 months observation of all included patients and in comparison of acute coronary syndrome with stable 
angina. Follow-up was available in 468 patients. Total MACE number is not equal to added components. Few 
events may occur in 1 patients
Parameter All patients (n = 468) ACS (n = 250) SA (n = 215) P-valuea
DOCE 9 (1.93%) 8 (3.2%) 1 (0.47%) < 0.03
MACE 14 (3.03%) 11 (4.44%) 3 (1.4%) 0.06
Death 2 (0.43%) 2 (0.8%) 0 (0.0%) 0.5
MI 8 (1.73%) 5 (2.01%) 3 (1.4%) 0.7
TLR with urgent PCI 7 (1.51%) 6 (2.41%) 1 (0.47%) 0.1
TVR with urgent CABG 0 (0.00%) 0 (0.00%) 0 (0.00%) –
Stent thrombosis 2 (0.43%) 2 (0.8%) 0 (0.0%) 0.5
Stent restenosis 10 (2.16%) 8 (3.21%) 2 (0.93%) 0.1
P-valuea – statistical significance for comparison of ACS vs. no ACS. ACS – acute coronary syndrome, CABG – coronary artery bypass grafting, DOCE – device-oriented 
composite endpoint, MACE – major adverse cardiovascular event, MI – myocardial infarction, PCI – percutaneous coronary interventions, SA – stable angina, TLR – 
target lesion revascularisation, TVR – target vessel revascularisation.
with urgent PCI was significantly more frequent in the 
UA group. A low rate of events was observed in the ob-
servation period. Furthermore, BVS implantation to more 
complex lesions seems to be safe and have no negative 
impact after 12 months of observation. Several studies 
have reported a  MACE rate between 2.6% and 10.7% 
[11]. Two recently published large analyses presented 
MACE in 5.0% after 12 months of observation [12, 13]. 
Our study showed a  lower incidence of MACE in com-
parison with the above-mentioned studies. The compos-
ite MACE endpoint rate also compares favourably with 
most of the available BVS implantation data. All-cause 
mortality after 6 months of observation was reported in 
1.3% in a recent all-comers registry [14]. Data from two 
other studies showed an incidence of all-cause death of 
0.8% after 12 months of follow-up [15, 16]. A lower inci-
dence of all-cause mortality was observed in our study in 
comparison with those studies; however, in the POLAR 
ACS and TROFI II trial no deaths occurred during one year 
and 6 months of follow-up, respectively [6, 17]. Data from 
a meta-analysis of BVS use showed MI in 5.2% and TLR 
in 3.0% [15]. The GHOST-EU registry also demonstrated 
higher incidence of these events in comparison with our 
study [14]. Device-oriented events are also crucial for 
evaluation of scaffold implantation efficacy and safety. 
Device-oriented composite endpoint was reported in 
4.7% and 4.1% of patients from two recently published 
analyses [12, 18]. Superior results were obtained in our 
study in terms of DOCE in comparison with large stud-
ies; however, another study showed occurrence in 1.1% 
[17]. ST appeared to be the most important limitation of 
polymeric scaffolds in the early phase after implantation 
[11]. The GHOST-EU registry reported definite/probable 
ST after 30 days and 12 months in 1.5% and 3.4%, re-
spectively [14]. A  recent meta-analysis demonstrated 
incidence in 1.26% of included patients [15]. In both 
studies the most reported events occurred during first 
30 days after the procedure, as in our research [14, 15]. 
Another study reported definite/probable ST in around 
1.1% [12]. ABSORB EXTEND showed similar incidence af-
ter 3 years of observation [19]. Recent research with 290 
consecutive STEMI patients demonstrated definite/prob-
able ST in 2.1% and 2.4 % after 30 days and 12 months 
of observation, respectively [18]. Despite enrolment of 
patients with more complex lesions, data in our study 
compare favourably with above-mentioned studies. The 
optimal clinical results from the current study could be 
the result of the aggressive strategy of lesion preparation 
and post-dilatation during scaffold delivery [9]. Direct 
comparisons between our analysis and different patient 
populations from other studies cannot be made; howev-
er, the low rates of ST, MACE, composite MACE endpoint 
and DOCE during 12 months of observation in our cohort 
supports this strategy of BVS implantation. Furthermore, 
two other studies using the offensive strategy of lesion 
preparation and routine high-pressure postdilation with 
intracoronary imaging showed no ST events despite in-
clusion of complex lesions [20–22]. Adequate antiplate-
let treatment is also important to achieve an optimal 
clinical outcome. For patients treated with BVS more 
aggressive antiplatelet therapy was postulated [11]. In 
a recent study clopidogrel, prasugrel and ticagrelor were 
prescribed in 73.2%, 26.2% and 0.6% of patients, respec-
tively [14]. Compared to our previous paper, ticagrelor 
was prescribed at discharge more often in the current 
study (6%) [9]. However, the TROFI II trial demonstrated 
optimal clinical outcomes after 6 months of observation 
with ticagrelor use at discharge in 46.2% and prasugrel in 
Łukasz Rzeszutko et al. Polish National Registry on BVS implantations
111Advances in Interventional Cardiology 2016; 12, 2 (44)
Figure 1. Kaplan-Meier curves for major adverse cardiovascular event incidence: A – MACE in all included pa-
tients, B – MACE in comparison of PCI indications (p = 0.09), C – MACE in comparison of ACS vs. SA (p = 0.06), 
D – MACE in comparison between patients with no or mild versus moderate or severe tortuosity at target ves-
sel (p = 0.6), E – MACE in comparison between patients with no or mild vs. moderate or heavy calcification at 
target vessel (p = 0.3), F – MACE in comparison between patients with or without bifurcation at target lesion 
(p = 0.6)
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Figure 2. Kaplan-Meier curves for device-oriented composite endpoint incidence: A – DOCE in all included pa-
tients, B – DOCE in comparison of PCI indications (p < 0.006), C – DOCE in comparison of ACS vs. SA (p < 0.03),  
D – DOCE in comparison between patients with no or mild versus moderate or severe tortuosity at target ves-
sel (p = 0.6), E – DOCE in comparison patients with no or mild versus moderate or heavy calcification at target 
vessel (p = 0.3), F – DOCE in comparison between patients with or without bifurcation at target lesion (p = 0.3)
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Table II. Clinical outcome, device-oriented composite endpoint and major adverse cardiovascular events after 
12 months of observation in comparison between patients with no or mild and moderate or severe tortuosity 
of target vessel. Follow-up was available in 468 patients. Total MACE number is not equal to added compo-
nents. Several events may occur in 1 patient
Parameter No and mild tortuosity (n = 387) Moderate and severe tortuosity (n = 78) P-value
DOCE 8 (2.08%) 1 (1.28%) 0.6
MACE 11 (2.86%) 3 (3.85%) 0.6
Death 1 (0.26%) 1 (1.28%) 0.3
MI 6 (1.55%) 2 (2.56%) 0.6
TLR with urgent PCI 7 (1.81%) 0 (0%) 0.6
TVR  with urgent CABG 0 (0%) 0 (0%) –
Stent thrombosis 2 (0.52%) 0 (0.00%) 1.0
Stent restenosis 9 (2.33%) 1 (1.28%) 1.0
CABG – coronary artery bypass grafting, DOCE – device-oriented composite endpoint, MACE – major adverse cardiovascular event, MI – myocardial infarction, 
PCI – percutaneous coronary interventions, TLR – target lesion revascularisation, TVR – target vessel revascularisation.
31.9% [17]. The above-mentioned higher rate of events 
in the UA group could be coincidental or the result of 
significantly lower prasugrel usage in comparison with 
other patients included in our study. The current use of 
BVS is still restricted to stable patients and non-complex 
lesions. A  recent study showed good results in an un-
selected population including lesions with higher com-
plexity, but the small sample size and short observation 
period are the main limitations of that study [23]. Oth-
er large studies including real-world patients with more 
complex lesions demonstrated optimal clinical outcome 
and efficacy comparable with that found in our research 
[12, 14, 24]. Proper lesion preparation and assessment 
by intra-coronary imaging may play an important role in 
treatment of ACS and lesions of higher complexity. 
The major limitations of this prospective study are 
the non-randomised manner and all the known draw-
backs of single-arm registry studies. Early outcomes in 
the presented registry are promising but do not exclude 
a significant increase of incidence of events in the longer 
term. This study was insufficient to examine low-fre-
quency events such as cardiac death and stent thrombo-
sis. Longer follow-up is required to assess occurrence of 
complications after BVS implantation. There is a poten-
tial bias caused by the loss of patients during follow-up 
and lack of some data. 
Conclusions
Bioresorbable vascular scaffold can be successfully 
and safely used for ACS treatment and in lesions of high-
Table III. Clinical outcome, device oriented composite endpoint and major adverse cardiovascular events after 
12 months observation in comparison between patients with no or mild and moderate or severe calcification 
of target vessel. Follow-up was available in 468 patients. Total MACE number is not equal to added compo-
nents. Few events may occur in 1 patients
Parameter No and mild calcification (n = 380) Moderate and severe calcification (n = 86) P-value
DOCE 6 (1.59%) 3 (3.49%) 0.3
MACE 10 (2.64%) 4 (4.65%) 0.3
Death 1 (0.26%) 1 (1.16%) 0.3
MI 5 (1.32%) 3 (3.49%) 0.2
TLR with urgent PCI 5 (1.32%) 2 (2.33%) 0.6
TVR  with urgent CABG 0 (0%) 0 (0%) –
Stent thrombosis 1 (0.26%) 1 (1.16%) 0.3
Stent restenosis 8 (2.11%) 2 (2.33%) 1.0
CABG – coronary artery bypass grafting, DOCE – device-oriented composite endpoint, MACE – major adverse cardiovascular event, MI – myocardial infarction, 
PCI – percutaneous coronary interventions, TLR – target lesion revascularisation, TVR – target vessel revascularisation.
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er complexity such as calcified lesions, severe tortuous 
vessels or bifurcation in the target vessel. The presented 
data are promising, but further investigation and longer-
term clinical follow-up of patients are required. 
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